You are here: Home » Companies » News
Business Standard

Bayer challenges cancer drug ruling favouring Natco

Patents office had allowed Natco to sell cheaper generic version of German firm's drug Nexavar


Drugmaker has said that it is challenging an order from the patents office that allowed Hyderabad-based Pharma to sell a cheap generic version of the German firm's drug in India. is used in the treatment of of the kidney and liver.

The patents office had stripped of its exclusive rights to sell Nexavar, saying most Indians could not afford it.

It told Pharma to sell the generic drug significantly more cheaply and pay a 6% royalty on sales.

Bayer said it had appealed against the ruling.

"We will rigorously continue to defend our intellectual property rights, which are a prerequisite for bringing innovative medicines to patients," a company spokesman said.

India's decision on was seen as a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms.

Separately, Bayer is suing another Indian drugmaker, Cipla, for patent infringement over Nexavar. has been selling generic Nexavar in India and it has slashed the price of the drug by 75% to Rs 6,840 a month.

First Published: Sun, May 06 2012. 16:11 IST